Peter G. Davis

ORCID: 0000-0001-6742-7314
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neonatal Respiratory Health Research
  • Neuroscience of respiration and sleep
  • Respiratory Support and Mechanisms
  • Congenital Diaphragmatic Hernia Studies
  • Infant Development and Preterm Care
  • Cardiac Arrest and Resuscitation
  • Airway Management and Intubation Techniques
  • Neonatal and fetal brain pathology
  • Congenital Heart Disease Studies
  • Ethics and Legal Issues in Pediatric Healthcare
  • Birth, Development, and Health
  • Child and Adolescent Health
  • Infant Nutrition and Health
  • Tracheal and airway disorders
  • Ultrasound in Clinical Applications
  • Ethics in medical practice
  • Family and Patient Care in Intensive Care Units
  • Palliative Care and End-of-Life Issues
  • Cardiovascular Conditions and Treatments
  • Non-Invasive Vital Sign Monitoring
  • Emergency and Acute Care Studies
  • Injury Epidemiology and Prevention
  • Fatty Acid Research and Health
  • Retinopathy of Prematurity Studies
  • Ethics in Clinical Research

The University of Melbourne
2016-2025

Royal Women's Hospital
2016-2025

Murdoch Children's Research Institute
2016-2025

Royal Ottawa Mental Health Centre
2014-2024

University of California, Davis
2021-2023

Stony Brook University
2023

University of the Cumberlands
2023

University of Zurich
2023

Parks Victoria
2022

James Cook University Hospital
2012-2022

Bronchopulmonary dysplasia is associated with ventilation and oxygen treatment. This randomized trial investigated whether nasal continuous positive airway pressure (CPAP), rather than intubation ventilation, shortly after birth would reduce the rate of death or bronchopulmonary in very preterm infants.We randomly assigned 610 infants who were born at 25-to-28-weeks' gestation to CPAP 5 minutes birth. We assessed outcomes 28 days age, 36 weeks' gestational before discharge.At 33.9% 307...

10.1056/nejmoa072788 article EN New England Journal of Medicine 2008-02-13

Methylxanthines reduce the frequency of apnea prematurity and need for mechanical ventilation during first seven days therapy. It is uncertain whether methylxanthines have other short- long-term benefits or risks in infants with very low birth weight.We randomly assigned 2006 weights 500 to 1250 g 10 life receive either caffeine placebo, until drug therapy was no longer needed. We evaluated short-term outcomes before discharge home.Of 963 who were remained alive at a postmenstrual age 36...

10.1056/nejmoa054065 article EN New England Journal of Medicine 2006-05-17

Methylxanthine therapy is commonly used for apnea of prematurity but in the absence adequate data on its efficacy and safety. It uncertain whether methylxanthines have long-term effects neurodevelopment growth.We randomly assigned 2006 infants with birth weights 500 to 1250 g receive either caffeine or placebo until was no longer needed. The primary outcome a composite death, cerebral palsy, cognitive delay (defined as Mental Development Index score <85 Bayley Scales Infant Development),...

10.1056/nejmoa073679 article EN New England Journal of Medicine 2007-11-07

The prophylactic administration of indomethacin reduces the frequency patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g). Whether prophylaxis confers any long-term benefits that outweigh risks drug-induced reductions renal, intestinal, cerebral blood flow is not known.

10.1056/nejm200106283442602 article EN New England Journal of Medicine 2001-06-28

OBJECTIVE: The goal was to define reference ranges for pulse oxygen saturation (Spo2) values in the first 10 minutes after birth infants who received no medical intervention delivery room. METHODS: Infants were eligible if a member of research team available record Spo2 immediately birth. excluded they supplemental or any type assisted ventilation. measured with sensor applied right hand wrist as soon possible birth; data collected every 2 seconds. RESULTS: We studied 468 and recorded 61650...

10.1542/peds.2009-1510 article EN PEDIATRICS 2010-05-04

Very preterm infants are prone to apnea and have an increased risk of death or disability. Caffeine therapy for prematurity reduces the rates cerebral palsy cognitive delay at 18 months age.To determine whether neonatal caffeine has lasting benefits newly apparent risks early school age.Five-year follow-up from 2005 2011 in 31 35 academic hospitals Canada, Australia, Europe, Israel, where 1932 2006 participants (96.3%) had been enrolled randomized, placebo-controlled Apnea Prematurity trial...

10.1001/jama.2011.2024 article EN JAMA 2012-01-17

Uncertainty exists about the benefit of dietary docosahexaenoic acid (DHA) on neurodevelopment preterm infants.To determine effect meeting estimated DHA requirement infants at 18 months' corrected age.Randomized, double-blind controlled trial enrolling born less than 33 weeks' gestation from April 2001 to October 2005 5 Australian tertiary hospitals, with follow-up months.High-DHA (approximately 1% total fatty acids) enteral feeds compared standard 0.3% day 2 4 life until term age.Bayley...

10.1001/jama.2008.945 article EN JAMA 2009-01-13

OBJECTIVE. Endotracheal intubation of newborn infants is a mandatory competence for many pediatric trainees. The Neonatal Resuscitation Program recommends 20-second limit attempts. Intubation attempts by junior doctors are frequently unsuccessful, and intubated between 20 30 seconds without apparent adverse effect. Little known about the proficiency more senior medical staff, time taken to determine endotracheal tube (ETT) position, or effects attempted on infants' heart rate (HR) oxygen...

10.1542/peds.2005-0901 article EN PEDIATRICS 2006-01-01

The use of high-flow nasal cannulae is an increasingly popular alternative to continuous positive airway pressure (CPAP) for noninvasive respiratory support very preterm infants (gestational age, <32 weeks) after extubation. However, data on the efficacy or safety such in this population are lacking.In multicenter, randomized, noninferiority trial, we assigned 303 receive treatment with either (5 6 liters per minute) CPAP (7 cm water) primary outcome was failure within 7 days. Noninferiority...

10.1056/nejmoa1300071 article EN New England Journal of Medicine 2013-10-10

BACKGROUND AND OBJECTIVES: Data from clinical trials support the use of continuous positive airway pressure (CPAP) for initial respiratory management in preterm infants, but there is concern regarding potential failure CPAP support. We aimed to examine incidence and explore outcomes Australian New Zealand Neonatal Network data 2007 2013. METHODS: inborn infants managed on outset were analyzed 2 gestational age ranges (25–28 29–32 completed weeks). Outcomes after (need intubation &amp;lt;72...

10.1542/peds.2015-3985 article EN PEDIATRICS 2016-06-30

Treatment with nasal high-flow therapy has efficacy similar to that of continuous positive airway pressure (CPAP) when used as postextubation support in neonates. The the primary means respiratory for preterm infants distress not been proved.

10.1056/nejmoa1603694 article EN New England Journal of Medicine 2016-09-21
Coming Soon ...